In its latest tie-up with a big pharma company, UK biotech MiNA Therapeutics Ltd. has announced a global research collaboration with Eli Lilly and Company, a sign of the interest being shown in the UK biotech’s small activating RNA (saRNA) technology platform, which aims to restore the normal functioning of genes rather than silencing them.
Small activating RNAs attract transcriptional complexes to target genes, increasing their expression, and could open up many currently “undruggable” targets...








